PharmaCom BioVet, Inc. Comments on Speculation of Corporate Restructuring

  PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is
pleased to comment on shareholder and investor speculation of any potential
amendments to the existing capital structure including the possibility of
any consolidation of the existing issued and outstanding common stock.

At the present time, PharmaCom BioVet, Inc. has no intention to amend the current capital structure of the company in any format. Any material changes to the corporate structure will require shareholder approval by way of a vote at either the annual general meeting or by way of a vote at an extraordinary meeting of shareholders.

Any potential amendment to the capital structure, as determined and therefore proposed by management to its shareholders, will be in the best interest of those who have invested in PharmaCom BioVet, Inc. and to the company as a whole.

About Us:

PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a potentially greater life expectancy and decreased suffering.

On behalf of the Board of Directors,
Mr. Gary Berthold

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Mr. Gary Berthold Tel: [phone] Url: www.PharmaComBioVet.com